EMEA-002735-PIP01-19-M01
Submitted by Anonymous (not verified) on 5 July 2024 - 15:00
EMEA-002735-PIP01-19-M01
Opinion/decision on a Paediatric investigation plan (PIP): Ontozry, cenobamate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0214/2023
Submitted by Anonymous (not verified) on 5 July 2024 - 14:46
Opinion/decision on a Paediatric investigation plan (PIP): Ontozry, cenobamate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0214/2023
EMEA-002229-PIP02-21-M01
Submitted by Anonymous (not verified) on 5 July 2024 - 14:43
EMEA-002229-PIP02-21-M01
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0186/2023
Submitted by Anonymous (not verified) on 5 July 2024 - 14:40
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0186/2023
Opinion/decision on a Paediatric investigation plan (PIP): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/02
Submitted by Anonymous (not verified) on 5 July 2024 - 14:21
Opinion/decision on a Paediatric investigation plan (PIP): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0242/2023
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0237/2023
Submitted by Anonymous (not verified) on 5 July 2024 - 14:07
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0237/2023
EMEA-001627-PIP01-14-M03
Submitted by Anonymous (not verified) on 5 July 2024 - 14:00
EMEA-001627-PIP01-14-M03
Opinion/decision on a Paediatric investigation plan (PIP): Filsuvez, birch bark, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0243/2023
Submitted by Anonymous (not verified) on 5 July 2024 - 13:59
Opinion/decision on a Paediatric investigation plan (PIP): Filsuvez, birch bark, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0243/2023
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0202/2023
Submitted by Anonymous (not verified) on 5 July 2024 - 13:56
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0202/2023
EMEA-001150-PIP02-13-M05
Submitted by Anonymous (not verified) on 5 July 2024 - 13:53
EMEA-001150-PIP02-13-M05